The CDMO built from science.
ExcellGene is a privately owned contract development and manufacturing organization (CDMO) based in Monthey, Switzerland and founded in 2001 by Prof. Dr. Florian M. Wurm and led since 2017 by Dr. Maria João Wurm, CEO.
F. Wurm is a former manager and scientist at Genentech Inc. and was among the pioneering scientists to generate manufacturing processes for the first pharmaceutical proteins made in CHO cells.
Maria J. De Jesus, now Maria J. Wurm, co-founding scientist of ExcellGene, invented and developed several breakthrough technologies as Senior Scientist at the Swiss Federal Institute of Technology (EPFL) in Lausanne. These inventions have had profound effects on cell line development, and some have attained global application in early R&D work towards clinical manufacturing of biologics. Both founders of ExcellGene are frequently invited to speak at conferences on the manufacturing of proteins with recombinant cells in bioreactors.
We deliver exceptional scientific solutions for those who hope and search for better health.
Meet the executives
Chief Executive Officer
Dr. Maria João Wurm, known through her published record as Maria De Jesus (publications), was the first employee of ExcellGene and built the company through increasing responsibilities in managerial tasks. Appointed Chief Executive Officer in January 2017, she previously was Chief Operating Officer for 8 years.
Maria, mother of two, is a frequently invited speaker on international conferences covering protein expression from animal cells and development and scale up of manufacturing approaches. Maria obtained a Master in Environmental Engineering from the University of Lisbon, Portugal and a PhD (Dr. es. Sci.) from the Swiss Federal Institute of Technology in Lausanne. Maria has published more than 40 highly referenced papers.
Chief Scientific Officer, Founder
Dr. Florian Maria Wurm is the founder and chairman of ExcellGene. He guided the scientific and technological innovations of the company as its’ Chief Scientific Officer.
As Professor of Biotechnology at the Swiss Federal Institute of Technology in Lausanne for 20 years (1995-2015) he and his students contributed a number of highly referenced innovations of the industry and provided deep insights into the genetics of CHO cells (> 250 publications).
Prior to his appointment in Lausanne, Wurm worked at Genentech Inc. in Process Sciences (1985-95) where he contributed to several products that became blockbuster drugs. Wurm is a trained geneticist (Diploma and PhD) from the Justus Liebig University in Giessen, Germany and was employed at Behringwerke AG in the Department of Virology after his studies during the early 1980s.
Chief Commercial Officer
Dr. George Hong joined ExcellGene in 2018 as its Chief Commercial Officer, bringing with him 20 years of experience in the biopharmaceutical, biotech, medical device (IVD), and life science industries. He has developed visions for organizations by identifying strategic growth opportunities and led teams from marketing, sales, distribution, finance, operations, QA/RA, R&D, engineering and operations to generate optimal outcome from P&L responsibilities.
As a leader, he is passionate about connecting with people and gauging their interests to confront challenges head on. He has always felt personally driven to do what he can for the betterment of those around him. George earned his Ph.D. in Molecular Medicine from the Duke University School of Medicine, and his MBA in Corporate Entrepreneurship from the Questrom School of Business at Boston University.
Chief Financial Officer
Martin Schmid holds an Executive MBA in integrated Management from the University of Applied Science Fribourg, Switzerland and a BBA in Finance.
Before joining ExcellGene SA and co-founding JMO Advisory and Associates Sarl, Martin developed and implemented tailored solutions in the fields of strategic planning, finance, project- and change-management as well as quality improvement audits in startup companies.
He acquired much experience as CEO, CFO and Director of strategic- and M&A-projects in major food transformation companies.
ExcellGene has assisted more than a hundred clients since inception, including 6 of the top 10 pharma companies, biotech companies, contract research organizations and academic institutions.
Clients choose ExcellGene due to our singular scientific expertise, and a highly personalized, communicative approach towards each project. This approach ensures that project objectives are met and delivered on time.
Who are our clients?
ExcellGene has a very deep understanding of the nuances of CHO cell clone development. We have seen in multiple projects that their thorough process ensures that each step is done right.David Block
For an academic vaccine developer like me, it is of utmost importance to build our research program with the support of a biotech company with which we have built a high level of confidence and trust. Communication has to be easy and transparent, and the delivery of our product has to be in purity and quantity as needed, so that the timing for starting a clinical trial matches our plans. This is exactly the experience I have with ExcellGene SA. In addition to it, as a science-driven company, they bring innovative and creative solutions to complex problems.Prof. François Spertini, MD
ExcellGene’s unique transient and stable protein expression technologies and manufacturing processes are based on proprietary CHOexpress™ cells – a most productive and robust cell host.
Similar performance is obtained for HEKexpress™ and for insect cells (FlyExpress™). The company’s services cover the value chain from DNA construction and transfection to scalable process and manufacture.
ExcellGene is proud to celebrate 17 years of successful service to the global bio-pharma industry by rapidly providing candidate molecules to the hands of researchers and by developing high-yielding cell culture based manufacturing processes for clinical production.
Ready to kickstart your projects?
©ExcellGene S.A., Route de l’Ile-aux-Bois 1A, 1870 Monthey, Switzerland.